I. Logeart

2.8k total citations · 1 hit paper
46 papers, 1.9k citations indexed

About

I. Logeart is a scholar working on Rheumatology, Pharmacology and Hematology. According to data from OpenAlex, I. Logeart has authored 46 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Rheumatology, 12 papers in Pharmacology and 8 papers in Hematology. Recurrent topics in I. Logeart's work include Rheumatoid Arthritis Research and Therapies (36 papers), Spondyloarthritis Studies and Treatments (23 papers) and Autoimmune and Inflammatory Disorders Research (8 papers). I. Logeart is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (36 papers), Spondyloarthritis Studies and Treatments (23 papers) and Autoimmune and Inflammatory Disorders Research (8 papers). I. Logeart collaborates with scholars based in France, Netherlands and United States. I. Logeart's co-authors include Maxime Dougados, Philippe Ravaud, Florence Tubach, Maxime Dougados, Bernard Combe, Gabriel Baron, Désirée van der Heijde, E. Martín‐Mola, H Awada and N. Hajjaj‐Hassouni and has published in prestigious journals such as Annals of the Rheumatic Diseases, Lara D. Veeken and Arthritis Research & Therapy.

In The Last Decade

I. Logeart

45 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: Results from a prospective multinational study

2012 316 citations Florence Tubach, Philippe Ravaud et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
I. Logeart France	24	1.4k	452	442	372	279	46	1.9k
Violaine Foltz France	24	1.2k 0.9×	300 0.7×	171 0.4×	365 1.0×	340 1.2×	78	1.8k
Hilde Berner Hammer Norway	33	2.4k 1.7×	619 1.4×	587 1.3×	731 2.0×	144 0.5×	138	3.2k
D. van der Heijde Netherlands	22	2.7k 1.9×	576 1.3×	555 1.3×	828 2.2×	403 1.4×	36	3.2k
Vibeke Strand United States	13	1.6k 1.1×	421 0.9×	252 0.6×	545 1.5×	333 1.2×	14	2.2k
Rossella De Angelis Italy	27	1.1k 0.8×	346 0.8×	493 1.1×	295 0.8×	173 0.6×	76	2.4k
Jeanne E. Hicks United States	24	777 0.5×	446 1.0×	233 0.5×	221 0.6×	115 0.4×	35	2.5k
Éric Houvenagel France	20	622 0.4×	268 0.6×	227 0.5×	188 0.5×	119 0.4×	68	1.3k
Suzanne Arends Netherlands	30	1.6k 1.2×	658 1.5×	966 2.2×	346 0.9×	66 0.2×	178	3.1k
P Bálint Hungary	18	1.2k 0.8×	328 0.7×	270 0.6×	506 1.4×	115 0.4×	58	1.9k
Pascal Zufferey Switzerland	22	764 0.5×	247 0.5×	301 0.7×	243 0.7×	140 0.5×	75	1.3k

Countries citing papers authored by I. Logeart

Since Specialization

Citations

This map shows the geographic impact of I. Logeart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I. Logeart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I. Logeart more than expected).

Fields of papers citing papers by I. Logeart

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by I. Logeart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I. Logeart. The network helps show where I. Logeart may publish in the future.

Co-authorship network of co-authors of I. Logeart

This figure shows the co-authorship network connecting the top 25 collaborators of I. Logeart. A scholar is included among the top collaborators of I. Logeart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with I. Logeart. I. Logeart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dougados, Maxime, Walter P. Maksymowych, Robert Landewé, et al.. (2018). Evaluation of the change in structural radiographic sacroiliac joint damage after 2 years of etanercept therapy (EMBARK trial) in comparison to a contemporary control cohort (DESIR cohort) in recent onset axial spondyloarthritis. Annals of the Rheumatic Diseases. 77(2). 221–227. 33 indexed citations

Ramiro, Sofía, Robert Landewé, Maxime Dougados, et al.. (2016). The Minimum Clinically Important Improvement and Patient-acceptable Symptom State in the BASDAI and BASFI for Patients with Ankylosing Spondylitis. The Journal of Rheumatology. 43(9). 1680–1686. 41 indexed citations

Maksymowych, Walter P., Maxime Dougados, Désirée van der Heijde, et al.. (2015). Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study. Annals of the Rheumatic Diseases. 75(7). 1328–1335. 80 indexed citations

Heijde, Désirée van der, et al.. (2014). When to Adjust Therapy in Patients with Rheumatoid Arthritis After Initiation of Etanercept plus Methotrexate or Methotrexate Alone: Findings from a Randomized Study (COMET). The Journal of Rheumatology. 41(10). 1922–1934. 8 indexed citations

Frazier, Aline, Maxime Dougados, Xavier Mariette, et al.. (2014). Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice. Joint Bone Spine. 81(4). 352–359. 34 indexed citations

Combe, Bernard, Nathalie Rincheval, Joëlle Bénessiano, et al.. (2013). Five-year Favorable Outcome of Patients with Early Rheumatoid Arthritis in the 2000s: Data from the ESPOIR Cohort. The Journal of Rheumatology. 40(10). 1650–1657. 36 indexed citations

Dougados, Maxime, Y. Brault, I. Logeart, et al.. (2012). Defining cut-off values for disease activity states and improvement scores for patient-reported outcomes: the example of the Rheumatoid Arthritis Impact of Disease (RAID). Arthritis Research & Therapy. 14(3). R129–R129. 59 indexed citations

Braun, Jürgen, Sándor Szántó, Bernard Combe, et al.. (2012). Continuous efficacy of etanercept in severe and advanced ankylosing spondylitis: results from a 12-week open-label extension of the SPINE study. Lara D. Veeken. 51(9). 1687–1696. 25 indexed citations

Mouterde, Gaël, Cédric Lukas, I. Logeart, et al.. (2011). Predictors of radiographic progression in the ESPOIR cohort: the season of first symptoms may influence the short-term outcome in early arthritis. Annals of the Rheumatic Diseases. 70(7). 1251–1256. 37 indexed citations

10.

Dougados, Maxime, Pascal Hilliquin, Patrice Fardellone, et al.. (2011). The Influence of the Definition of Patient Global Assessment in Assessment of Disease Activity According to the Disease Activity Score (DAS28) in Rheumatoid Arthritis. The Journal of Rheumatology. 38(11). 2326–2328. 14 indexed citations

11.

Mandl, Péter, Péter Bálint, Y. Brault, et al.. (2011). Metrologic properties of ultrasound versus clinical evaluation of synovitis in rheumatoid arthritis: Results of a multicenter, randomized study. Arthritis & Rheumatism. 64(4). 1272–1282. 41 indexed citations

12.

Ornetti, Paul, et al.. (2010). Validation of a numerical rating scale to assess functional impairment in hip and knee osteoarthritis: comparison with the WOMAC function scale. Annals of the Rheumatic Diseases. 70(5). 740–746. 67 indexed citations

13.

Lukas, Cédric, Francis Guillemin, Robert Landewé, et al.. (2009). Factors determining a DMARD initiation in early inflammatory arthritis patients. The ESPOIR cohort study.. PubMed. 27(1). 84–91. 13 indexed citations

14.

Séror, Raphaèle, Florence Tubach, Gabriel Baron, et al.. (2007). Individualising the Western Ontario and McMaster Universities osteoarthritis index (WOMAC) function subscale: incorporating patient priorities for improvement to measure functional impairment in hip or knee osteoarthritis. Annals of the Rheumatic Diseases. 67(4). 494–499. 16 indexed citations

15.

Dougados, Maxime, Anne Le Hénanff, I. Logeart, & Philippe Ravaud. (2007). Short-Term Efficacy of Rofecoxib and Diclofenac in Acute Shoulder Pain: A Placebo-Controlled Randomized Trial. PubMed. 2(3). e9–e9. 13 indexed citations

16.

Combe, Bernard, Joëlle Bénessiano, Francis Bérenbaum, et al.. (2007). The ESPOIR cohort: A ten-year follow-up of early arthritis in France. Joint Bone Spine. 74(5). 440–445. 135 indexed citations

17.

Tubach, Florence, Maxime Dougados, Bruno Falissard, et al.. (2006). Feeling good rather than feeling better matters more to patients. Arthritis Care & Research. 55(4). 526–530. 162 indexed citations

18.

Bannwarth, B, et al.. (2004). Prescription du rofécoxib en pratique médicale courante : résultats d'une enquête française. La Revue de Médecine Interne. 25(10). 710–714. 1 indexed citations

19.

Tubach, Florence, Gabriel Baron, Philippe Ravaud, et al.. (2003). Evaluation of clinically relevant changes and states in symptomatic outcome variables in osteoarthritis. Queensland's institutional digital repository (The University of Queensland). 48(9). 276–276. 5 indexed citations

20.

Goupille, Philippe, I. Logeart, & Bernard Combe. (2003). Naturalistic survey on nonsteroidal antiinflammatory treatment in patients with musculoskeletal pain. Joint Bone Spine. 70(3). 219–225. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact